Lisinopril - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)

Targets (1)Biointeractions (1)

Identification

Name

Lisinopril

Accession Number

DB00722 (APRD00560)

Type

Small Molecule

Groups

Approved, Investigational

Description

Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline

[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline

Lisinopril

Lisinopril anhydrous

Lisinoprilum

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Lisinopril dihydrate	E7199S1YWR	83915-83-7	CZRQXSDBMCMPNJ-ZUIPZQNBSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Lisinopril	Tablet	5 mg	Oral	Actavis Pharma Company	2007-10-17	Not applicable	Canada
Act Lisinopril	Tablet	10 mg	Oral	Actavis Pharma Company	2007-10-17	Not applicable	Canada
Act Lisinopril	Tablet	20 mg	Oral	Actavis Pharma Company	2007-10-17	Not applicable	Canada
Auro-lisinopril	Tablet	10 mg	Oral	Auro Pharma Inc	2013-02-12	Not applicable	Canada
Auro-lisinopril	Tablet	5 mg	Oral	Auro Pharma Inc	2013-02-12	Not applicable	Canada
Auro-lisinopril	Tablet	20 mg	Oral	Auro Pharma Inc	2013-02-12	Not applicable	Canada
Dom-lisinopril	Tablet	5 mg	Oral	Dominion Pharmacal	2008-04-16	Not applicable	Canada
Dom-lisinopril	Tablet	10 mg	Oral	Dominion Pharmacal	2008-04-16	Not applicable	Canada
Dom-lisinopril	Tablet	20 mg	Oral	Dominion Pharmacal	2008-04-16	Not applicable	Canada
Ipg-lisinopril	Tablet	20 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Ipg-lisinopril	Tablet	5 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Ipg-lisinopril	Tablet	10 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Jamp-lisinopril	Tablet	10 mg	Oral	Jamp Pharma Corporation	2011-02-04	Not applicable	Canada
Jamp-lisinopril	Tablet	20 mg	Oral	Jamp Pharma Corporation	2011-02-04	Not applicable	Canada
Jamp-lisinopril	Tablet	5 mg	Oral	Jamp Pharma Corporation	2011-02-04	Not applicable	Canada
Lisinopril	Tablet	5 mg	Oral	Sivem Pharmaceuticals Ulc	2012-06-11	Not applicable	Canada
Lisinopril	Tablet	40 mg	Oral	Sivem Pharmaceuticals Ulc	Not applicable	Not applicable	Canada
Lisinopril	Tablet	20 mg	Oral	Meliapharm Inc	2008-03-12	2014-06-25	Canada
Lisinopril	Tablet	5 mg	Oral	Sorres Pharma Inc	2009-06-22	2014-06-20	Canada
Lisinopril	Tablet	10 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Lisinopril	Tablet	5 mg	Oral	Meliapharm Inc	2008-03-12	2014-06-25	Canada
Lisinopril	Tablet	10 mg	Oral	Sivem Pharmaceuticals Ulc	2012-06-11	Not applicable	Canada
Lisinopril	Tablet	10 mg	Oral	Sorres Pharma Inc	2009-06-22	2014-06-20	Canada
Lisinopril	Tablet	20 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Lisinopril	Tablet	10 mg	Oral	Meliapharm Inc	2008-03-12	2014-06-25	Canada
Lisinopril	Tablet	20 mg	Oral	Sivem Pharmaceuticals Ulc	2012-06-11	Not applicable	Canada
Lisinopril	Tablet	5 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Lisinopril	Tablet	20 mg	Oral	Sorres Pharma Inc	2009-06-22	2014-06-20	Canada
Lisinopril Tablets	Tablet	20 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Lisinopril Tablets	Tablet	10 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Lisinopril Tablets	Tablet	5 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Lisinopril Tablets USP	Tablet	20 mg	Oral	Lupin Pharmaceuticals	Not applicable	Not applicable	Canada
Lisinopril Tablets USP	Tablet	5 mg	Oral	Lupin Pharmaceuticals	Not applicable	Not applicable	Canada
Lisinopril Tablets USP	Tablet	10 mg	Oral	Lupin Pharmaceuticals	Not applicable	Not applicable	Canada
Mar-lisinopril	Tablet	5 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mar-lisinopril	Tablet	10 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mar-lisinopril	Tablet	20 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mint-lisinopril	Tablet	5 mg	Oral	Mint Pharmaceuticals Inc	2008-10-28	2012-08-02	Canada
Mint-lisinopril	Tablet	10 mg	Oral	Mint Pharmaceuticals Inc	2008-10-28	2012-08-02	Canada
Mint-lisinopril	Tablet	20 mg	Oral	Mint Pharmaceuticals Inc	2008-10-28	2012-08-02	Canada
Mylan-lisinopril	Tablet	10 mg	Oral	Mylan Pharmaceuticals	2007-10-17	Not applicable	Canada
Mylan-lisinopril	Tablet	20 mg	Oral	Mylan Pharmaceuticals	2007-10-17	Not applicable	Canada
Mylan-lisinopril	Tablet	5 mg	Oral	Mylan Pharmaceuticals	2007-10-17	Not applicable	Canada
Nu-lisinopril	Tablet	20 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	20 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	5 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	40 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	5 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	40 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	10 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-lisinopril	Tablet	10 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
PMS-lisinopril	Tablet	10 mg	Oral	Pharmascience Inc	2007-10-17	Not applicable	Canada
PMS-lisinopril	Tablet	20 mg	Oral	Pharmascience Inc	2007-10-17	Not applicable	Canada
PMS-lisinopril	Tablet	5 mg	Oral	Pharmascience Inc	2007-10-17	Not applicable	Canada
Prinivil	Tablet	10 mg	Oral	Merck Ltd.	1990-12-31	Not applicable	Canada
Prinivil	Tablet	20 mg/1	Oral	Merck Sharp & Dohme Limited	1987-12-29	Not applicable	US
Prinivil	Tablet	20 mg	Oral	Merck Ltd.	1990-12-31	Not applicable	Canada
Prinivil	Tablet	5 mg/1	Oral	Merck Sharp & Dohme Limited	1987-12-29	Not applicable	US
Prinivil	Tablet	10 mg/1	Oral	Merck Sharp & Dohme Limited	1987-12-29	Not applicable	US
Prinivil	Tablet	5 mg	Oral	Merck Ltd.	1990-12-31	2015-03-02	Canada
Prinivil	Tablet	2.5 mg	Oral	Merck Ltd.	2000-01-05	2005-06-23	Canada
Pro-lisinopril - 10	Tablet	10 mg	Oral	Pro Doc Limitee	2008-07-03	Not applicable	Canada
Pro-lisinopril - 20	Tablet	20 mg	Oral	Pro Doc Limitee	2008-07-03	Not applicable	Canada
Pro-lisinopril - 5	Tablet	5 mg	Oral	Pro Doc Limitee	2008-07-03	Not applicable	Canada
Qbrelis	Solution	1 mg/mL	Oral	Silvergate Pharmaceuticals, Inc.	2016-08-29	Not applicable	US
Ran-lisinopril	Tablet	10 mg	Oral	Ranbaxy Inc.	2007-10-17	Not applicable	Canada
Ran-lisinopril	Tablet	20 mg	Oral	Ranbaxy Inc.	2007-10-17	Not applicable	Canada
Ran-lisinopril	Tablet	5 mg	Oral	Ranbaxy Inc.	2007-10-17	Not applicable	Canada
Ratio-lisinopril P	Tablet	5 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2007-10-17	2014-09-19	Canada
Ratio-lisinopril P	Tablet	10 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2007-10-17	2014-09-19	Canada
Ratio-lisinopril P	Tablet	20 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2007-10-17	2014-09-19	Canada
Ratio-lisinopril Z	Tablet	20 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2007-10-17	2014-09-19	Canada
Ratio-lisinopril Z	Tablet	5 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2007-10-17	2014-09-19	Canada
Ratio-lisinopril Z	Tablet	10 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2007-10-17	2014-09-19	Canada
Riva-lisinopril	Tablet	10 mg	Oral	Laboratoire Riva Inc	2007-10-26	Not applicable	Canada
Riva-lisinopril	Tablet	5 mg	Oral	Laboratoire Riva Inc	2007-10-26	Not applicable	Canada
Riva-lisinopril	Tablet	20 mg	Oral	Laboratoire Riva Inc	2007-10-26	Not applicable	Canada
Sandoz Lisinopril	Tablet	10 mg	Oral	Sandoz Canada Incorporated	2007-10-17	Not applicable	Canada
Sandoz Lisinopril	Tablet	5 mg	Oral	Sandoz Canada Incorporated	2007-10-17	Not applicable	Canada
Sandoz Lisinopril	Tablet	20 mg	Oral	Sandoz Canada Incorporated	2007-10-17	Not applicable	Canada
Teva-lisinopril (type P)	Tablet	10 mg	Oral	Teva	2007-10-17	Not applicable	Canada
Teva-lisinopril (type P)	Tablet	20 mg	Oral	Teva	2007-10-17	Not applicable	Canada
Teva-lisinopril (type P)	Tablet	5 mg	Oral	Teva	2007-10-17	Not applicable	Canada
Teva-lisinopril (type Z)	Tablet	5 mg	Oral	Teva	2007-10-17	Not applicable	Canada
Teva-lisinopril (type Z)	Tablet	10 mg	Oral	Teva	2007-10-17	Not applicable	Canada
Teva-lisinopril (type Z)	Tablet	20 mg	Oral	Teva	2007-10-17	Not applicable	Canada
Zestril	Tablet	5 mg/1	Oral	Astra Zeneca Lp	2009-11-11	2018-10-31	US
Zestril	Tablet	40 mg/1	Oral	Astra Zeneca Lp	2010-03-26	2018-10-31	US
Zestril	Tablet	10 mg/1	Oral	ALMATICA PHARMA INC.	2015-04-07	Not applicable	US
Zestril	Tablet	20 mg	Oral	Astra Zeneca	1994-12-31	Not applicable	Canada
Zestril	Tablet	40 mg/1	Oral	ALMATICA PHARMA INC.	2015-04-07	Not applicable	US
Zestril	Tablet	30 mg/1	Oral	Astra Zeneca Lp	2010-09-22	2018-10-31	US
Zestril	Tablet	2.5 mg/1	Oral	ALMATICA PHARMA INC.	2015-04-07	Not applicable	US
Zestril	Tablet	20 mg/1	Oral	ALMATICA PHARMA INC.	2015-04-07	Not applicable	US
Zestril	Tablet	10 mg/1	Oral	Astra Zeneca Lp	2009-08-28	2018-03-31	US
Zestril	Tablet	2.5 mg/1	Oral	Astra Zeneca Lp	2011-09-02	2018-04-30	US
Zestril	Tablet	5 mg	Oral	Astra Zeneca	1994-12-31	Not applicable	Canada
Zestril	Tablet	5 mg/1	Oral	ALMATICA PHARMA INC.	2015-04-07	Not applicable	US
Zestril	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2009-05-13	Not applicable	US
Zestril	Tablet	30 mg/1	Oral	ALMATICA PHARMA INC.	2015-04-07	Not applicable	US
Zestril	Tablet	20 mg/1	Oral	Astra Zeneca Lp	2009-05-13	2018-05-31	US
Zestril	Tablet	10 mg	Oral	Astra Zeneca	1994-12-31	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-lisinopril Tablet (type P) - 10mg	Tablet	10 mg	Oral	Apotex Corporation	1996-10-30	2001-08-02	Canada
Apo-lisinopril Tablet (type P) - 20mg	Tablet	20 mg	Oral	Apotex Corporation	1996-10-30	2001-08-02	Canada
Apo-lisinopril Tablet (type P) - 40mg	Tablet	40 mg	Oral	Apotex Corporation	1996-12-30	2001-08-02	Canada
Apo-lisinopril Tablet (type P) - 5mg	Tablet	5 mg	Oral	Apotex Corporation	1996-10-30	2001-08-02	Canada
Apo-lisinopril Tablet 10 mg	Tablet	10 mg	Oral	Apotex Corporation	1996-10-30	Not applicable	Canada
Apo-lisinopril Tablet 20 mg	Tablet	20 mg	Oral	Apotex Corporation	1996-10-30	Not applicable	Canada
Apo-lisinopril Tablet 40 mg	Tablet	40 mg	Oral	Apotex Corporation	1996-10-30	Not applicable	Canada
Apo-lisinopril Tablet 5 mg	Tablet	5 mg	Oral	Apotex Corporation	1996-10-30	Not applicable	Canada
Lisinopril	Tablet	5 mg/1	Oral	Amerincan Health Packaging	2013-12-23	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Accord Healthcare Limited	2013-09-15	2017-09-30	US
Lisinopril	Tablet	5 mg/1	Oral	Rebel Distributors	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2013-05-28	2017-01-05	US
Lisinopril	Tablet	10 mg/301	Oral	Northwind Pharmaceuticals	2014-05-20	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Blu Pharmceuticals Llc	2009-02-02	2017-05-06	US
Lisinopril	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2015-06-09	Not applicable	US
Lisinopril	Tablet	10 1/1	Oral	Northwind Pharmaceuticals	2014-11-17	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	bryant ranch prepack	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2006-01-13	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-08-20	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2012-11-07	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Blue Point Laboratories	2017-08-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2016-04-27	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Amerincan Health Packaging	2005-09-22	2015-12-29	US
Lisinopril	Tablet	20 mg/1	Oral	Aurobindo Pharma	2006-02-22	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2005-09-22	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Nu Care Pharmaceuticals,inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Par Pharmaceutical	2002-07-01	2017-12-31	US
Lisinopril	Tablet	2.5 mg/1	Oral	West Ward Pharmaceutical	2013-02-13	2016-02-18	US
Lisinopril	Tablet	40 mg/1	Oral	Blue Point Laboratories	2014-02-04	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2016-03-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Contract Pharmacy Services Pa	2002-08-02	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	A S Medication Solutions	2016-04-29	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	Major	2015-06-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	West Ward Pharmaceutical	2013-02-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-11-30	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-08-28	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2009-09-22	2016-11-01	US
Lisinopril	Tablet	40 mg/1	Oral	Eon Labs, Inc.	2015-06-09	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Par Pharmaceutical	2002-07-01	2018-09-30	US
Lisinopril	Tablet	40 mg/1	Oral	Cardinal Health	2009-12-18	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	Proficient Rx LP	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2015-07-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Cardinal Health	2006-01-13	2017-04-27	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2016-10-04	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Blue Point Laboratories	2014-02-04	2017-09-30	US
Lisinopril	Tablet	30 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Citron Pharma LLC	2006-02-22	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2013-12-23	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Kaiser Foundations Hospitals	2008-11-03	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2013-09-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Camber Pharmaceuticals	2013-11-15	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Mylan Institutional	2002-08-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Golden State Medical Supply	2015-01-07	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2006-01-13	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	West Ward Pharmaceutical	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Safecor Health, LLC	2014-09-30	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	bryant ranch prepack	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-04-05	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2010-04-20	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Eon Labs, Inc.	2015-12-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	A S Medication Solutions	2013-02-13	2017-06-20	US
Lisinopril	Tablet	5 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-02-28	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2012-12-31	2017-01-27	US
Lisinopril	Tablet	2.5 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-05	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Rebel Distributors	2008-02-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-02	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Aidarex Pharmaceuticals LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Ranbaxy Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	bryant ranch prepack	2002-07-01	2017-11-30	US
Lisinopril	Tablet	2.5 mg/1	Oral	Actavis Pharma Company	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	International Laboratories, Llc	2008-02-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Cardinal Health	2006-01-13	2017-04-27	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2016-08-19	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Ready Meds	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2017-02-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Proficient Rx LP	2011-11-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Citron Pharma LLC	2006-02-22	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2016-10-18	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	International Laboratories, Inc.	2012-02-20	2016-10-13	US
Lisinopril	Tablet	10 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2015-01-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Lupin Pharmaceuticals	2017-03-07	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-11-30	US
Lisinopril	Tablet	5 mg/1	Oral	Hikma Pharmaceutical	2013-08-22	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Proficient Rx LP	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Solco healthcare U.S., LLC	2017-08-30	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Aidarex Pharmaceuticals LLC	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Red Pharm Drug, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Apotex Corporation	2008-06-25	2017-02-28	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-05-02	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	TYA Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2017-09-07	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Actavis Pharma Company	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2011-09-29	2016-11-08	US
Lisinopril	Tablet	20 mg/1	Oral	Solco healthcare U.S., LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	bryant ranch prepack	2011-11-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Lake Erie Medical Quality Care Products LLC	2012-03-27	Not applicable	US
Lisinopril	Tablet, film coated	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2017-04-05	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2017-06-27	US
Lisinopril	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-11-07	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2015-10-08	2017-01-27	US
Lisinopril	Tablet	5 mg/1	Oral	Liberty Pharmaceuticals, Inc.	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2016-03-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Camber Pharmaceuticals	2013-11-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Mylan Institutional	2002-08-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Golden State Medical Supply	2015-01-07	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2013-06-24	2017-12-06	US
Lisinopril	Tablet	40 mg/1	Oral	West Ward Pharmaceutical	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2011-04-20	2016-10-13	US
Lisinopril	Tablet	2.5 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	bryant ranch prepack	2006-01-13	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2017-01-10	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2010-04-20	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Eon Labs, Inc.	2015-08-19	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Unit Dose Services	2016-03-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Blenheim Pharmacal, Inc.	2015-02-19	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2013-05-08	2017-01-19	US
Lisinopril	Tablet	20 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-05	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2013-02-28	2016-10-21	US
Lisinopril	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Unit Dose Services	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Ranbaxy Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	A S Medication Solutions	2016-12-22	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	Actavis Pharma Company	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	International Laboratories, Llc	2008-02-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2006-01-13	2017-04-27	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2016-09-12	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Blue Point Laboratories	2017-08-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Ready Meds	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Aidarex Pharmaceuticals LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Citron Pharma LLC	2006-02-22	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-10-25	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Physicians Total Care, Inc.	2009-02-16	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Remedy Repack	2017-08-18	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Proficient Rx LP	2011-11-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Red Pharm Drug, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Golden State Medical Supply	2015-01-07	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2006-01-13	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Solco healthcare U.S., LLC	2017-08-30	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Rxchange Co	2014-11-12	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	St. Marys Medical Park Pharmacy	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-12-03	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Med Vantx, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	A S Medication Solutions	2014-05-16	2018-01-31	US
Lisinopril	Tablet	20 mg/1	Oral	Major	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2007-02-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Mesource Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2017-06-14	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Proficient Rx LP	2011-11-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	A S Medication Solutions	2011-11-01	2017-06-20	US
Lisinopril	Tablet, film coated	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-04-19	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Amerincan Health Packaging	2013-12-23	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Accord Healthcare Limited	2013-07-30	2017-11-30	US
Lisinopril	Tablet	40 mg/1	Oral	Rebel Distributors	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2013-03-20	2017-02-22	US
Lisinopril	Tablet	5 mg/1	Oral	Camber Pharmaceuticals	2013-11-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Blenheim Pharmacal, Inc.	2010-05-20	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Mc Kesson Contract Packaging	2011-09-07	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Cardinal Health	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-11-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2015-01-07	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	TYA Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Amerincan Health Packaging	2005-09-22	2015-12-05	US
Lisinopril	Tablet	5 mg/1	Oral	Blue Point Laboratories	2014-02-04	2017-11-30	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2009-12-18	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Solco healthcare U.S., LLC	2017-08-30	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Par Pharmaceutical	2002-07-01	2018-01-31	US
Lisinopril	Tablet	10 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Accord Healthcare Limited	2016-03-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Red Pharm Drug, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Accord Healthcare Limited	2013-09-15	2017-10-31	US
Lisinopril	Tablet	2.5 mg/1	Oral	Eon Labs, Inc.	2002-07-01	2017-09-30	US
Lisinopril	Tablet	2.5 mg/1	Oral	A S Medication Solutions	2006-01-13	2017-06-20	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-10-28	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2013-03-18	2017-02-01	US
Lisinopril	Tablet	5 mg/1	Oral	Mylan Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	International Laboratories, Llc	2015-05-12	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2012-10-05	2016-10-13	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2016-07-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Aurobindo Pharma	2006-02-22	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Blue Point Laboratories	2016-09-07	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Blue Point Laboratories	2015-07-06	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Keltman Pharmaceuticals Inc.	2010-12-10	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2009-08-19	2016-11-01	US
Lisinopril	Tablet	40 mg/1	Oral	Mc Kesson Contract Packaging	2011-09-16	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Proficient Rx LP	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Blue Point Laboratories	2014-02-04	2017-12-31	US
Lisinopril	Tablet	40 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Accord Healthcare Limited	2016-03-21	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-04-12	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-11-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Eon Labs, Inc.	2002-07-01	2017-11-30	US
Lisinopril	Tablet	40 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	40 mg/1	Oral	Mylan Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	International Laboratories, Llc	2008-02-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2005-09-22	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2016-08-11	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Unit Dose Services	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2005-11-17	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2017-06-27	US
Lisinopril	Tablet	2.5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Aidarex Pharmaceuticals LLC	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	5 mg/1	Oral	Apotex Corporation	2008-02-18	2017-02-28	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-01-30	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2011-07-13	2016-10-28	US
Lisinopril	Tablet	5 mg/1	Oral	Solco healthcare U.S., LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	A S Medication Solutions	2017-03-07	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-11-01	Not applicable	US
Lisinopril	Tablet, film coated	2.5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Stat Rx USA	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2013-05-16	2017-01-12	US
Lisinopril	Tablet	5 mg/1	Oral	Northwind Pharmaceuticals	2014-07-30	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Blu Pharmceuticals Llc	2009-02-02	2017-05-06	US
Lisinopril	Tablet	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2015-05-21	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	bryant ranch prepack	2005-11-17	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Directrx	2017-02-20	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Blue Point Laboratories	2017-08-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2017-03-06	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Physicians Total Care, Inc.	2008-04-10	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2012-08-27	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Contract Pharmacy Services Pa	2002-07-02	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2016-04-25	2017-06-20	US
Lisinopril	Tablet	5 mg/1	Oral	Major	2015-06-15	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Aidarex Pharmaceuticals LLC	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Hikma Pharmaceutical	2013-08-22	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Central Texas Community Health Centers	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Solco healthcare U.S., LLC	2017-08-30	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Rxchange Co	2014-11-18	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2017-05-12	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Apotex Corporation	2002-10-09	2017-02-28	US
Lisinopril	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-12-03	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	TYA Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Cardinal Health	2012-10-05	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Actavis Pharma Company	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-07-19	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Solco healthcare U.S., LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Blue Point Laboratories	2016-10-14	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Proficient Rx LP	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Amerincan Health Packaging	2015-10-01	2017-02-28	US
Lisinopril	Tablet, film coated	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Amerincan Health Packaging	2013-12-23	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Accord Healthcare Limited	2013-09-15	2018-01-31	US
Lisinopril	Tablet	10 mg/1	Oral	Rebel Distributors	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	H.J. Harkins Company	2005-11-17	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Northwind Pharmaceuticals	2014-11-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Blu Pharmceuticals Llc	2009-02-02	2017-05-06	US
Lisinopril	Tablet	10 mg/1	Oral	Blenheim Pharmacal, Inc.	2009-12-16	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	2019-10-31	US
Lisinopril	Tablet	40 mg/1	Oral	bryant ranch prepack	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Life Line Home Care Services	2010-08-12	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2015-01-07	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Unit Dose Services	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Amerincan Health Packaging	2005-09-22	2015-12-29	US
Lisinopril	Tablet	30 mg/1	Oral	Aurobindo Pharma	2006-02-22	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2009-12-18	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Legacy Pharmaceutical Packaging	2017-03-07	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Par Pharmaceutical	2002-07-01	2018-09-30	US
Lisinopril	Tablet	2.5 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Carilion Materials Management	2002-07-01	2017-09-30	US
Lisinopril	Tablet	10 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2018-05-01	US
Lisinopril	Tablet	5 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2016-03-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Red Pharm Drug, Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2016-06-02	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Major	2015-06-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	West Ward Pharmaceutical	2013-02-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	40 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-08-28	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Remedy Repack	2011-07-19	2016-10-28	US
Lisinopril	Tablet	5 mg/1	Oral	Eon Labs, Inc.	2002-07-01	2017-11-30	US
Lisinopril	Tablet	40 mg/1	Oral	Par Pharmaceutical	2002-07-01	2018-01-31	US
Lisinopril	Tablet	2.5 mg/1	Oral	Cardinal Health	2009-12-18	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2015-06-15	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Aurobindo Pharma	2006-02-22	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Proficient Rx LP	2015-05-23	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Blue Point Laboratories	2015-07-06	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Avera Mc Kennan Hospital	2016-04-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Citron Pharma LLC	2006-02-22	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2016-10-31	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2013-12-23	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Kaiser Foundations Hospitals	2008-11-03	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2013-09-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Camber Pharmaceuticals	2013-11-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Mylan Institutional	2002-08-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Golden State Medical Supply	2015-01-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2016-04-25	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	West Ward Pharmaceutical	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2002-07-01	2017-12-31	US
Lisinopril	Tablet	10 mg/1	Oral	Safecor Health, LLC	2014-10-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	bryant ranch prepack	2006-01-13	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-05-16	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-04-05	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2010-04-20	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Eon Labs, Inc.	2015-05-21	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2013-02-13	2017-06-20	US
Lisinopril	Tablet	2.5 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-01-14	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2013-07-05	2017-01-24	US
Lisinopril	Tablet	5 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-05	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2013-09-19	2016-12-09	US
Lisinopril	Tablet	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2017-06-27	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Ranbaxy Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2017-02-14	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Actavis Pharma Company	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	International Laboratories, Llc	2008-02-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2006-01-13	2017-04-27	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2016-09-06	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-01	2017-12-31	US
Lisinopril	Tablet	10 mg/1	Oral	Ready Meds	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Eon Labs, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Citron Pharma LLC	2006-02-22	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Directrx	2016-08-22	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	International Laboratories, Inc.	2012-02-20	2016-10-13	US
Lisinopril	Tablet	5 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2015-01-07	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Lupin Pharmaceuticals	2017-03-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Mylan Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	International Laboratories, Llc	2015-05-12	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Cardinal Health	2002-07-01	2016-10-13	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2016-08-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-06-10	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2017-06-27	US
Lisinopril	Tablet	20 mg/1	Oral	Aidarex Pharmaceuticals LLC	2013-02-13	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Aidarex Pharmaceuticals LLC	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Red Pharm Drug, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Golden State Medical Supply	2015-01-07	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-01-30	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2011-03-29	2016-10-19	US
Lisinopril	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	St. Marys Medical Park Pharmacy	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2017-01-12	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2010-04-20	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Blenheim Pharmacal, Inc.	2015-02-19	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2013-05-13	2017-01-18	US
Lisinopril	Tablet	30 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-05	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Blu Pharmceuticals Llc	2009-02-02	2017-05-06	US
Lisinopril	Tablet	30 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Ranbaxy Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Blue Point Laboratories	2017-08-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cambridge Therapeutics Technologies, Llc	2015-05-23	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Physicians Total Care, Inc.	2005-07-25	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2012-08-27	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-06-09	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Clinical Solutions Wholsesale	2017-03-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Med Vantx, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	A S Medication Solutions	2014-05-16	2017-11-30	US
Lisinopril	Tablet	40 mg/1	Oral	Major	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Amerincan Health Packaging	2014-06-02	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2007-02-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Mc Kesson Contract Packaging	2011-09-08	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Amerincan Health Packaging	2014-12-15	2015-12-29	US
Lisinopril	Tablet	20 mg/1	Oral	Blue Point Laboratories	2002-07-01	2017-12-31	US
Lisinopril	Tablet	20 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Accord Healthcare Limited	2016-03-21	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Eon Labs, Inc.	2002-07-01	2017-11-30	US
Lisinopril	Tablet	5 mg/1	Oral	A S Medication Solutions	2013-02-13	2017-06-20	US
Lisinopril	Tablet	2.5 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Contract Pharmacy Services Pa	2010-08-12	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	A S Medication Solutions	2016-04-27	2017-06-20	US
Lisinopril	Tablet	10 mg/1	Oral	Major	2015-06-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Legacy Pharmaceutical Packaging	2010-10-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2009-07-30	2016-11-01	US
Lisinopril	Tablet	40 mg/1	Oral	Proficient Rx LP	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Blue Point Laboratories	2014-07-31	2017-12-31	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2011-09-29	2016-11-15	US
Lisinopril	Tablet	2.5 mg/1	Oral	Kaiser Foundations Hospitals	2013-08-05	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Accord Healthcare Limited	2016-03-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-04-12	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2016-09-29	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Eon Labs, Inc.	2002-07-01	2017-11-30	US
Lisinopril	Tablet	30 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	30 mg/1	Oral	Mylan Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	International Laboratories, Llc	2008-02-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2005-09-22	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2016-08-15	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	A S Medication Solutions	2011-11-01	2017-06-20	US
Lisinopril	Tablet	30 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Unit Dose Services	2016-03-21	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2005-11-17	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Hikma Pharmaceutical	2013-08-22	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Proficient Rx LP	2011-11-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Aidarex Pharmaceuticals LLC	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Apotex Corporation	2008-04-17	2017-02-28	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-01-30	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2011-05-19	2016-11-15	US
Lisinopril	Tablet	10 mg/1	Oral	Solco healthcare U.S., LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	A S Medication Solutions	2006-01-13	2017-06-20	US
Lisinopril	Tablet	5 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2017-01-13	Not applicable	US
Lisinopril	Tablet, film coated	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-04-19	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Stat Rx USA	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2013-05-28	2017-02-14	US
Lisinopril	Tablet	40 mg/1	Oral	Northwind Pharmaceuticals	2015-03-10	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Blu Pharmceuticals Llc	2009-02-02	2017-05-06	US
Lisinopril	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2015-05-23	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	bryant ranch prepack	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Directrx	2017-02-20	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Blue Point Laboratories	2017-08-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Unit Dose Services	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Physicians Total Care, Inc.	2007-04-12	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Cardinal Health	2012-08-27	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Eon Labs, Inc.	2015-05-23	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-02-17	US
Lisinopril	Tablet	5 mg/1	Oral	Blenheim Pharmacal, Inc.	2015-02-19	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2013-05-08	2017-01-20	US
Lisinopril	Tablet	10 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-05	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2013-05-20	2016-11-01	US
Lisinopril	Tablet	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Unit Dose Services	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Ranbaxy Inc.	2002-07-02	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	A S Medication Solutions	2016-06-02	2017-06-20	US
Lisinopril	Tablet	10 mg/1	Oral	Actavis Pharma Company	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	International Laboratories, Llc	2008-02-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2006-01-13	2017-04-27	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2016-09-08	2017-05-31	US
Lisinopril	Tablet	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2017-08-02	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Ready Meds	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cambridge Therapeutics Technologies, Llc	2015-05-23	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Citron Pharma LLC	2006-02-22	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	A S Medication Solutions	2006-01-13	2017-06-20	US
Lisinopril	Tablet	40 mg/1	Oral	Physicians Total Care, Inc.	2004-08-25	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2017-08-11	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Lupin Pharmaceuticals	2017-03-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2017-04-27	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Hikma Pharmaceutical	2013-08-22	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Remedy Repack	2016-12-08	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Solco healthcare U.S., LLC	2017-08-30	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Rxchange Co	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2017-05-17	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Apotex Corporation	2008-01-22	2017-02-28	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Med Vantx, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2014-05-16	2017-09-30	US
Lisinopril	Tablet	10 mg/1	Oral	Major	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Lake Erie Medical Quality Care Products LLC	2012-03-27	2017-02-09	US
Lisinopril	Tablet	40 mg/1	Oral	Solco healthcare U.S., LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Proficient Rx LP	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2014-04-04	2017-08-24	US
Lisinopril	Tablet, film coated	30 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Amerincan Health Packaging	2013-12-23	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Accord Healthcare Limited	2013-09-15	2017-08-31	US
Lisinopril	Tablet	20 mg/1	Oral	Rebel Distributors	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Aidarex Pharmaceuticals LLC	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2013-02-26	2016-12-22	US
Lisinopril	Tablet	2.5 mg/1	Oral	Camber Pharmaceuticals	2013-11-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Blenheim Pharmacal, Inc.	2009-12-16	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Legacy Pharmaceutical Packaging	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Mc Kesson Contract Packaging	2011-09-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2002-07-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-01-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2015-01-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	TYA Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Unit Dose Services	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Amerincan Health Packaging	2005-09-22	2015-12-29	US
Lisinopril	Tablet	40 mg/1	Oral	Aurobindo Pharma	2006-02-22	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Cardinal Health	2009-12-18	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Solco healthcare U.S., LLC	2017-08-30	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Par Pharmaceutical	2002-07-01	2018-09-30	US
Lisinopril	Tablet	5 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Accord Healthcare Limited	2016-03-21	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2018-05-01	US
Lisinopril	Tablet	10 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Red Pharm Drug, Inc.	2005-11-17	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Accord Healthcare Limited	2013-09-15	2018-01-31	US
Lisinopril	Tablet	5 mg/1	Oral	West Ward Pharmaceutical	2013-02-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-10-29	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Unit Dose Services	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Mylan Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	International Laboratories, Llc	2015-05-12	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2012-10-05	2016-10-13	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2015-06-15	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Aurobindo Pharma	2006-02-22	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	TYA Pharmaceuticals	2002-07-01	2017-11-30	US
Lisinopril	Tablet	20 mg/1	Oral	Blue Point Laboratories	2015-07-06	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Remedy Repack	2017-04-04	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2017-06-27	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2016-11-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2013-12-23	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Kaiser Foundations Hospitals	2008-11-03	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2013-09-15	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Camber Pharmaceuticals	2013-11-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Mylan Institutional	2002-08-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Golden State Medical Supply	2015-01-07	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-06-09	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	West Ward Pharmaceutical	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Remedy Repack	2010-09-16	2016-10-13	US
Lisinopril	Tablet	40 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	bryant ranch prepack	2006-01-13	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	St. Marys Medical Park Pharmacy	2002-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-04-05	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2010-04-20	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Accord Healthcare Limited	2016-03-21	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Lupin Pharmaceuticals	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-11-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Eon Labs, Inc.	2002-07-01	2017-12-31	US
Lisinopril	Tablet	5 mg/1	Oral	A S Medication Solutions	2002-07-01	2017-06-20	US
Lisinopril	Tablet	20 mg/1	Oral	Mylan Pharmaceuticals	2002-07-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	International Laboratories, Llc	2015-05-12	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cardinal Health	2012-10-05	2016-10-13	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2016-08-01	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-06-14	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Clinical Solutions Wholsesale	2006-01-13	2017-06-27	US
Lisinopril	Tablet	10 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Aidarex Pharmaceuticals LLC	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2017-05-08	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Apotex Corporation	2008-06-26	2017-02-28	US
Lisinopril	Tablet	40 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-01-30	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Remedy Repack	2011-06-21	2016-10-13	US
Lisinopril	Tablet	2.5 mg/1	Oral	Solco healthcare U.S., LLC	2011-11-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	A S Medication Solutions	2017-03-07	2017-06-20	US
Lisinopril	Tablet	10 mg/1	Oral	Remedy Repack	2015-12-23	2017-04-14	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2017-01-17	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2010-04-20	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Stat Rx USA	2005-11-17	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Remedy Repack	2013-05-14	2017-01-11	US
Lisinopril	Tablet	40 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-05	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Blu Pharmceuticals Llc	2009-02-02	2017-05-06	US
Lisinopril	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2002-07-01	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-03-15	Not applicable	US
Lisinopril	Tablet	30 mg/1	Oral	Ranbaxy Inc.	2006-05-15	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	bryant ranch prepack	2006-01-13	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Blue Point Laboratories	2017-08-01	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Wockhardt	2007-04-19	Not applicable	US
Lisinopril	Tablet	5 mg/1	Oral	Cambridge Therapeutics Technologies, Llc	2015-05-23	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Physicians Total Care, Inc.	2007-09-17	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Cardinal Health	2012-08-27	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2016-04-25	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Clinical Solutions Wholsesale	2017-03-07	Not applicable	US
Lisinopril	Tablet	10 mg/1	Oral	Contract Pharmacy Services Pa	2010-08-12	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	A S Medication Solutions	2014-05-16	2018-01-31	US
Lisinopril	Tablet	5 mg/1	Oral	Major	2002-07-01	Not applicable	US
Lisinopril	Tablet	2.5 mg/1	Oral	Dispensing Solutions, Inc.	2005-11-17	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2007-02-15	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Mc Kesson Contract Packaging	2011-09-09	Not applicable	US
Lisinopril	Tablet	20 mg/1	Oral	Remedy Repack	2015-03-23	Not applicable	US
Lisinopril	Tablet	40 mg/1	Oral	Blue Point Laboratories	2014-02-04	2017-11-30	US
Lisinopril 10mg	Tablet	10 mg/1	Oral	Mc Kesson Contract Packaging	2013-08-01	Not applicable	US
Lisinopril 2.5mg	Tablet	2.5 mg/1	Oral	Mc Kesson Contract Packaging	2013-08-01	Not applicable	US
Lisinopril 20mg	Tablet	20 mg/1	Oral	Mc Kesson Contract Packaging	2013-08-01	Not applicable	US
Lisinopril 40mg	Tablet	40 mg/1	Oral	Mc Kesson Contract Packaging	2013-08-01	Not applicable	US
Lisinopril 5mg	Tablet	5 mg/1	Oral	Mc Kesson Contract Packaging	2013-08-01	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Acebitor	GlaxoSmithKline
Acemin	AstraZeneca
Acerbon	AstraZeneca
Acinopril	sanofi-aventis
Bellisin	Ranbaxy
Biopril	Biochem
Dapril	Medochemie
Fibsol	Sigma
Fisopril	Sanofi-Aventis
Hipril	Micro Labs
Linopril	Klinger (Brazil)
Lisipril	Hexal (Czech Republic), Orion (Finland)
Noperten	Dexa (Indonesia)
Presiten	Magnachem
Ranolip	Ranbaxy
Ranopril	Ranbaxy
Rantex	Biotech
Sinopren	Ranbaxy
Sinopril	Eczacibasi (Russia)
Tensopril	Merck

Brand mixtures

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Apo-lisinopril/hctz	Hydrochlorothiazide Lisinopril	Tablet	Oral	Apotex Corporation	2007-09-05	Not applicable	Canada
Ava-lisinopril Hct	Hydrochlorothiazide Lisinopril	Tablet	Oral	Avanstra Inc	2011-08-18	2014-08-21	Canada
Lisinopril and HCTZ	Hydrochlorothiazide Lisinopril	Tablet	Oral	Northwind Pharmaceuticals	2014-07-10	Not applicable	US
Lisinopril and Hydrochlorothiazide	Hydrochlorothiazide Lisinopril	Tablet	Oral	IVAX Pharmaceuticals, Inc.	2002-07-01	Not applicable	US
Lisinopril and Hydrochlorthiazide	Hydrochlorothiazide Lisinopril	Tablet	Oral	Remedy Repack	2011-04-04	2016-10-13	US
Lisinopril with Hydrochlorothiazide	Hydrochlorothiazide Lisinopril	Tablet	Oral	Aphena Pharma Solutions Tennessee, Inc.	2002-07-08	Not applicable	US
Lisinopril/hctz (type Z)	Hydrochlorothiazide Lisinopril	Tablet	Oral	Sanis Health Inc	2011-06-10	Not applicable	Canada
Lisnopril/hctz (type P)	Hydrochlorothiazide Lisinopril	Tablet	Oral	Sanis Health Inc	Not applicable	Not applicable	Canada
Lytensopril	L-Arginine Lisinopril	Kit		Physician Therapeutics Llc	2011-07-07	Not applicable	US
Lytensopril-90	L-Arginine Lisinopril	Kit		Physician Therapeutics Llc	2011-07-07	2016-10-13	US
Mylan-lisinopril Hctz	Hydrochlorothiazide Lisinopril	Tablet	Oral	Mylan Pharmaceuticals	2007-11-21	2017-01-09	Canada
Ntp-lisinopril/hctz (type P)	Hydrochlorothiazide Lisinopril	Tablet	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-lisinopril/hctz (type Z)	Hydrochlorothiazide Lisinopril	Tablet	Oral	Teva	Not applicable	Not applicable	Canada
Nu-lisinopril/hctz	Hydrochlorothiazide Lisinopril	Tablet	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Prinzide	Hydrochlorothiazide Lisinopril	Tablet	Oral	Merck Ltd.	1992-12-31	2014-10-10	Canada
Sandoz Lisinopril Hct	Hydrochlorothiazide Lisinopril	Tablet	Oral	Sandoz Canada Incorporated	2007-11-21	Not applicable	Canada
Teva-lisinopril/hctz (type P)	Hydrochlorothiazide Lisinopril	Tablet	Oral	Teva	2007-11-22	Not applicable	Canada
Teva-lisinopril/hctz (type Z)	Hydrochlorothiazide Lisinopril	Tablet	Oral	Teva	2007-11-21	Not applicable	Canada
Zestoretic	Hydrochlorothiazide Lisinopril	Tablet	Oral	ALMATICA PHARMA INC.	2015-04-15	Not applicable	US

Categories

UNII

7Q3P4BS2FD

CAS number

76547-98-3

Weight

Average: 405.4879
Monoisotopic: 405.226371117

Chemical Formula

C₂₁H₃₁N₃O₅

InChI Key

RLAWWYSOJDYHDC-BZSNNMDCSA-N

InChI

InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1

IUPAC Name

(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid

SMILES

NCCCC[[email protected]](N[[email protected]@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[[email protected]]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications

Pharmacodynamics

Lisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of lisinopril by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Lisinopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Lisinopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Angiotensin-converting enzyme	Protein	yes	inhibitor	Human	P12821	details

Absorption

Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food

Volume of distribution

Not Available

Protein binding

Lisinopril does not appear to be bound to serum proteins other than ACE.

Metabolism

Does not undergo metabolism, excreted unchanged in urine.

Route of elimination

Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine.

Half life

Effective half life of accumulation following multiple dosing is 12 hours.

Clearance

10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg]

Toxicity

Symptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD₅₀= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Lisinopril Action Pathway	Drug action	SMP00150

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Lisinopril.	Experimental
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Lisinopril.	Approved, Investigational
Acebutolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Acebutolol.	Approved
Aceclofenac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Aceclofenac.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Lisinopril.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Acetazolamide.	Approved, Vet Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Lisinopril is combined with Adapalene.	Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Lisinopril.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Lisinopril.	Experimental
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Lisinopril.	Approved, Investigational
Aliskiren	Aliskiren may increase the hyperkalemic activities of Lisinopril.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Lisinopril.	Approved, Investigational
Allopurinol	The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Lisinopril.	Approved
Alogliptin	The risk or severity of adverse effects can be increased when Alogliptin is combined with Lisinopril.	Approved
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Lisinopril.	Approved, Illicit, Investigational
Alprenolol	Lisinopril may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Lisinopril.	Approved, Investigational
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lisinopril.	Experimental
Amifostine	Lisinopril may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Lisinopril.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Lisinopril.	Illicit, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Lisinopril.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may decrease the antihypertensive activities of Lisinopril.	Approved
Amiodarone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Lisinopril.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Lisinopril.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Lisinopril.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Lisinopril is combined with Amphotericin B.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Lisinopril is combined with Amyl Nitrite.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when Lisinopril is combined with HMPL-004.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Anisodamine.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Antipyrine.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Lisinopril.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Acetovanillone.	Investigational
Apomorphine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Apraclonidine.	Approved
Apremilast	The risk or severity of adverse effects can be increased when Lisinopril is combined with Apremilast.	Approved, Investigational
Aprotinin	Aprotinin may decrease the antihypertensive activities of Lisinopril.	Approved, Withdrawn
Ardeparin	Ardeparin may increase the hyperkalemic activities of Lisinopril.	Approved, Withdrawn
Aripiprazole	Aripiprazole may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Arotinolol.	Approved
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Lisinopril.	Approved, Investigational
Atazanavir	The serum concentration of Atazanavir can be increased when it is combined with Lisinopril.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Lisinopril.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be increased when it is combined with Lisinopril.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Lisinopril.	Approved, Investigational
Azapropazone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Azapropazone.	Withdrawn
Azathioprine	Lisinopril may increase the myelosuppressive activities of Azathioprine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisinopril.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Balsalazide.	Approved, Investigational
Barbexaclone	Barbexaclone may increase the hypotensive activities of Lisinopril.	Experimental
Barbital	Barbital may increase the hypotensive activities of Lisinopril.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Barnidipine.	Approved
Bemiparin	Bemiparin may increase the hyperkalemic activities of Lisinopril.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Lisinopril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Lisinopril.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Lisinopril.	Withdrawn
Benoxaprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Benoxaprofen.	Withdrawn
Bepridil	Lisinopril may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Lisinopril.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Lisinopril.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Betulinic Acid.	Investigational
Bimatoprost	Lisinopril may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Lisinopril.	Approved
Boceprevir	The serum concentration of Lisinopril can be decreased when it is combined with Boceprevir.	Withdrawn
Bortezomib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Bortezomib.	Approved, Investigational
Bosentan	Bosentan may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Lisinopril.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Lisinopril.	Approved
Bretylium	The risk or severity of adverse effects can be increased when Lisinopril is combined with Bretylium.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Lisinopril.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Lisinopril.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Bromfenac.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.	Approved, Investigational
Bucillamine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Bucillamine.	Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Lisinopril may increase the hypotensive activities of Bupranolol.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Lisinopril.	Approved
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Lisinopril.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Lisinopril.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Lisinopril.	Experimental
Canagliflozin	Canagliflozin may increase the hyperkalemic activities of Lisinopril.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril.	Approved
Candoxatril	Candoxatril may increase the hypotensive activities of Lisinopril.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Captopril.	Approved
Carbamazepine	The metabolism of Lisinopril can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Carbetocin.	Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Lisinopril.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Lisinopril.	Withdrawn
Carprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	The risk or severity of adverse effects can be increased when Carteolol is combined with Lisinopril.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Castanospermine.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Celecoxib.	Approved, Investigational
Celiprolol	Lisinopril may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Lisinopril.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Lisinopril.	Withdrawn
Certoparin	Certoparin may increase the hyperkalemic activities of Lisinopril.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Chlorotrianisene can be decreased when it is combined with Lisinopril.	Withdrawn
Chlorpromazine	The serum concentration of Chlorpromazine can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Lisinopril.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Trisalicylate-choline.	Approved
Cilazapril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Cilnidipine.	Approved
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Lisinopril.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Lisinopril.	Approved, Investigational
Ciprofloxacin	Lisinopril may increase the arrhythmogenic activities of Ciprofloxacin.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be increased when it is combined with Lisinopril.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Lisinopril.	Approved
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Lisinopril.	Approved
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Lisinopril.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Clofarabine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Lisinopril.	Approved, Investigational
Clomipramine	The serum concentration of Clomipramine can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Lisinopril.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Clonixin.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Lisinopril.	Approved, Nutraceutical
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Lisinopril.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Lisinopril.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Lisinopril.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Lisinopril is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Lisinopril.	Approved
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Lisinopril.	Approved
Cryptenamine	Lisinopril may increase the hypotensive activities of Cryptenamine.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Curcumin.	Investigational
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Lisinopril.	Approved
D-Limonene	The risk or severity of adverse effects can be increased when Lisinopril is combined with D-Limonene.	Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lisinopril.	Approved
Dabrafenib	The serum concentration of Dabrafenib can be increased when it is combined with Lisinopril.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Lisinopril.	Approved
Dalteparin	Dalteparin may increase the hyperkalemic activities of Lisinopril.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Lisinopril.	Investigational
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Lisinopril.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Lisinopril.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Lisinopril.	Approved
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Lisinopril.	Approved
dersalazine	dersalazine may decrease the antihypertensive activities of Lisinopril.	Investigational
Deserpidine	Lisinopril may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Lisinopril is combined with Desflurane.	Approved
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Lisinopril.	Approved
Dexamethasone	The serum concentration of Dexamethasone can be increased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril.	Approved, Vet Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Lisinopril.	Approved, Illicit, Vet Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Lisinopril.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenamide.	Approved
Dienestrol	The serum concentration of Dienestrol can be decreased when it is combined with Lisinopril.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lisinopril.	Approved
Diflunisal	Diflunisal may decrease the antihypertensive activities of Lisinopril.	Approved
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Lisinopril.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Lisinopril.	Approved
Dihydralazine	Lisinopril may increase the hypotensive activities of Dihydralazine.	Investigational
Dihydroergotamine	The serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lisinopril.	Illicit
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Lisinopril.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Lisinopril.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Dorzolamide	Lisinopril may increase the hypotensive activities of Dorzolamide.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Lisinopril.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Lisinopril.	Approved
Doxepin	The serum concentration of Doxepin can be increased when it is combined with Lisinopril.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Lisinopril.	Approved, Investigational
Drospirenone	Lisinopril may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Droxicam.	Approved
Duloxetine	Lisinopril may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Duvelisib.	Investigational
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Lisinopril.	Approved
E-6201	The risk or severity of adverse effects can be increased when Lisinopril is combined with E6201.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Ebselen.	Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Lisinopril.	Approved
Efonidipine	Lisinopril may increase the hypotensive activities of Efonidipine.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Lisinopril.	Approved, Investigational
Empagliflozin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Lisinopril.	Approved, Vet Approved
Enalaprilat	Lisinopril may increase the hypotensive activities of Enalaprilat.	Approved
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Lisinopril.	Approved, Investigational
Enoxaparin	Enoxaparin may increase the hyperkalemic activities of Lisinopril.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Lisinopril.	Approved, Investigational
Epirizole	The risk or severity of adverse effects can be increased when Lisinopril is combined with Epirizole.	Approved
Eplerenone	Eplerenone may increase the hyperkalemic activities of Lisinopril.	Approved
Epoprostenol	Lisinopril may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril.	Approved
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.	Approved
Ergonovine	The serum concentration of Ergonovine can be increased when it is combined with Lisinopril.	Approved
Ergotamine	The serum concentration of Ergotamine can be increased when it is combined with Lisinopril.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Lisinopril.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Esmirtazapine	The serum concentration of Esmirtazapine can be increased when it is combined with Lisinopril.	Investigational
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril.	Approved
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Lisinopril.	Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Lisinopril.	Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Lisinopril.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Lisinopril is combined with Etanercept.	Approved, Investigational
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lisinopril.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Etofenamate.	Approved
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Lisinopril.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Etoricoxib.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Lisinopril.	Approved
Evening primrose oil	The risk or severity of adverse effects can be increased when Lisinopril is combined with Evening primrose oil.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Lisinopril.	Approved
exisulind	The risk or severity of adverse effects can be increased when Lisinopril is combined with exisulind.	Investigational
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Lisinopril.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Felodipine.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Fenbufen.	Approved
Fenoldopam	Lisinopril may increase the hypotensive activities of Fenoldopam.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Fenoprofen.	Approved
Fesoterodine	The serum concentration of Fesoterodine can be increased when it is combined with Lisinopril.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Lisinopril.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Lisinopril.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Lisinopril is combined with Fimasartan.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Floctafenine.	Approved, Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Flunixin.	Vet Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Flurbiprofen.	Approved, Investigational
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Lisinopril.	Approved
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril.	Experimental
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Lisinopril.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Lisinopril.	Approved, Vet Approved
Garlic	The serum concentration of Lisinopril can be decreased when it is combined with Garlic.	Approved
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Lisinopril.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Lisinopril.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Lisinopril.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Lisinopril.	Withdrawn
Guanabenz	Guanabenz may increase the hypotensive activities of Lisinopril.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Lisinopril.	Approved
Guanethidine	Lisinopril may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Guanfacine.	Approved, Investigational
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Lisinopril.	Approved
Halothane	The risk or severity of adverse effects can be increased when Lisinopril is combined with Halothane.	Approved, Vet Approved
Heparin	Heparin may increase the hyperkalemic activities of Lisinopril.	Approved, Investigational
Hexamethonium	Lisinopril may increase the hypotensive activities of Hexamethonium.	Experimental
Hexestrol	The serum concentration of Hexestrol can be decreased when it is combined with Lisinopril.	Withdrawn
Hexobarbital	Hexobarbital may increase the hypotensive activities of Lisinopril.	Approved
Higenamine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Higenamine.	Investigational
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Lisinopril.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Hydroflumethiazide	Lisinopril may increase the hypotensive activities of Hydroflumethiazide.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Lisinopril.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Ibuproxam.	Withdrawn
Icatibant	Icatibant may decrease the antihypertensive activities of Lisinopril.	Approved
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Lisinopril.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Lisinopril.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Lisinopril.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Lisinopril.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Indapamide.	Approved
Indenolol	Lisinopril may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The serum concentration of Indinavir can be increased when it is combined with Lisinopril.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Lisinopril.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Indoprofen.	Withdrawn
Indoramin	Lisinopril may increase the hypotensive activities of Indoramin.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Lisinopril.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Lisinopril.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Lisinopril.	Approved, Investigational
Iron	The risk or severity of adverse effects can be increased when Lisinopril is combined with Iron.	Approved
Iron Dextran	The risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.	Approved, Vet Approved
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Lisinopril.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isoflurane.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxicam.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Lisinopril.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Kebuzone.	Experimental
Ketanserin	Lisinopril may increase the hypotensive activities of Ketanserin.	Investigational
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Lisinopril.	Approved
Ketoconazole	The serum concentration of Ketoconazole can be increased when it is combined with Lisinopril.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Ketorolac.	Approved
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Lisinopril.	Approved
Lacidipine	Lisinopril may increase the hypotensive activities of Lacidipine.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Lisinopril.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Lisinopril.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Lisinopril.	Approved, Investigational
Lanthanum carbonate	The serum concentration of Lisinopril can be decreased when it is combined with Lanthanum carbonate.	Approved
Latanoprost	Latanoprost may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Lisinopril.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Lisinopril.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Lisinopril.	Approved
Lercanidipine	Lercanidipine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Lisinopril.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Levobupivacaine.	Approved
Levodopa	Lisinopril may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be increased when it is combined with Lisinopril.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Lisinopril.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Lisinopril is combined with Levosimendan.	Approved, Investigational
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Lisinopril.	Approved
Lisofylline	The risk or severity of adverse effects can be increased when Lisinopril is combined with Lisofylline.	Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Lisinopril.	Approved
Lofexidine	Lisinopril may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Lisinopril.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Lornoxicam.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Lisinopril.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Loxoprofen.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Lumiracoxib.	Approved, Investigational
Macitentan	Lisinopril may increase the hypotensive activities of Macitentan.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Magnesium salicylate.	Approved
Manidipine	Lisinopril may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Masoprocol.	Approved
Mebanazine	Mebanazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Lisinopril.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Meclofenamic acid.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Mefenamic acid.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Meloxicam.	Approved, Vet Approved
Mesalazine	Mesalazine may decrease the antihypertensive activities of Lisinopril.	Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Lisinopril.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Lisinopril is combined with Metamizole.	Withdrawn
Methallenestril	The serum concentration of Methallenestril can be decreased when it is combined with Lisinopril.	Experimental
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Lisinopril.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Lisinopril.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Lisinopril.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lisinopril.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Lisinopril is combined with Methyldopa.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Lisinopril.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Lisinopril.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Lisinopril.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Metipranolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Lisinopril.	Approved
Metoprolol	The risk or severity of adverse effects can be increased when Metoprolol is combined with Lisinopril.	Approved, Investigational
Metyrosine	Lisinopril may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Lisinopril may increase the hypotensive activities of Mibefradil.	Withdrawn
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Lisinopril.	Approved, Illicit
Minaprine	Minaprine may increase the hypotensive activities of Lisinopril.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Lisinopril.	Approved
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Lisinopril.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be increased when it is combined with Lisinopril.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Lisinopril.	Approved, Investigational
Mizoribine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Mizoribine.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Lisinopril.	Approved
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Lisinopril.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Lisinopril.	Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Lisinopril.	Approved, Investigational
Moxonidine	Lisinopril may increase the hypotensive activities of Moxonidine.	Approved
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Lisinopril.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Mycophenolic acid.	Approved
Nabilone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nabilone.	Approved, Investigational
Nabumetone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nabumetone.	Approved
Nadolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nadolol.	Approved
Nadroparin	Nadroparin may increase the hyperkalemic activities of Lisinopril.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Naftifine.	Approved
Naftopidil	Lisinopril may increase the hypotensive activities of Naftopidil.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Lisinopril.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Naproxen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Naproxen.	Approved, Vet Approved
Nebivolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Lisinopril.	Approved, Withdrawn
Nelfinavir	The serum concentration of Nelfinavir can be increased when it is combined with Lisinopril.	Approved
Nepafenac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nepafenac.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nesiritide.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Lisinopril.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Lisinopril.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Lisinopril.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Niflumic Acid.	Approved
Niguldipine	Lisinopril may increase the hypotensive activities of Niguldipine.	Experimental
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Lisinopril.	Approved, Investigational
Nilvadipine	Lisinopril may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nimesulide.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Lisinopril.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Lisinopril.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Lisinopril.	Approved
Nitrendipine	Lisinopril may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nitric Oxide.	Approved
Nitroaspirin	Nitroaspirin may decrease the antihypertensive activities of Lisinopril.	Investigational
Nitroglycerin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Lisinopril.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Lisinopril.	Approved
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Lisinopril.	Approved
Obinutuzumab	Lisinopril may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Lisinopril.	Withdrawn
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Lisinopril.	Approved, Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Olopatadine.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Olsalazine.	Approved
Omapatrilat	Lisinopril may increase the hypotensive activities of Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Lisinopril.	Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Lisinopril.	Investigational
Orgotein	The risk or severity of adverse effects can be increased when Lisinopril is combined with Orgotein.	Vet Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Lisinopril.	Approved
Oxaprozin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Oxaprozin.	Approved
Oxprenolol	Lisinopril may increase the hypotensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Oxyphenbutazone.	Withdrawn
Paclitaxel	The serum concentration of Paclitaxel can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Lisinopril.	Approved, Investigational
Papaverine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Parecoxib.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Lisinopril.	Approved
Parnaparin	Parnaparin may increase the hyperkalemic activities of Lisinopril.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Lisinopril.	Approved
Penbutolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Penbutolol.	Approved, Investigational
Pentobarbital	Pentobarbital may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Pentolinium	Lisinopril may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Perindopril.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Lisinopril.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Phenobarbital	The serum concentration of Phenobarbital can be increased when it is combined with Lisinopril.	Approved
Phenoxybenzamine	Lisinopril may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Lisinopril.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Phenylbutazone.	Approved, Vet Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pimecrolimus.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Lisinopril.	Approved
Pinacidil	Lisinopril may increase the hypotensive activities of Pinacidil.	Withdrawn
Pindolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pindolol.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pipamperone.	Approved
Piretanide	Piretanide may increase the hypotensive activities of Lisinopril.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pirfenidone.	Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Lisinopril.	Approved
Piroxicam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Piroxicam.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Lisinopril.	Approved
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Polythiazide	Lisinopril may increase the hypotensive activities of Polythiazide.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Lisinopril.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Lisinopril.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pramipexole.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Lisinopril.	Approved
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Lisinopril.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pregabalin.	Approved, Illicit, Investigational
Primidone	Primidone may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Propacetamol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Propacetamol.	Approved
Propofol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Lisinopril.	Approved, Investigational
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Lisinopril.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Lisinopril.	Approved
PTC299	The risk or severity of adverse effects can be increased when Lisinopril is combined with PTC299.	Investigational
Quetiapine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Quinapril.	Approved, Investigational
Quinethazone	Quinethazone may increase the hypotensive activities of Lisinopril.	Approved
Quinidine	The serum concentration of Quinidine can be increased when it is combined with Lisinopril.	Approved
Quinine	Quinine may increase the hypotensive activities of Lisinopril.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Lisinopril.	Approved
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Lisinopril.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Lisinopril.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypotensive activities of Lisinopril.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Lisinopril is combined with Remifentanil.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Lisinopril.	Approved
Rescinnamine	Lisinopril may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Lisinopril.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Resveratrol.	Experimental, Investigational
Reviparin	Reviparin may increase the hyperkalemic activities of Lisinopril.	Approved
Rifampicin	The serum concentration of Rifampicin can be increased when it is combined with Lisinopril.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Lisinopril.	Approved, Investigational
Rilmenidine	Lisinopril may increase the hypotensive activities of Rilmenidine.	Investigational
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Lisinopril.	Approved
Risperidone	Lisinopril may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritonavir	The serum concentration of Ritonavir can be increased when it is combined with Lisinopril.	Approved, Investigational
Rituximab	Lisinopril may increase the hypotensive activities of Rituximab.	Approved
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Lisinopril.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Rofecoxib.	Investigational, Withdrawn
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Lisinopril.	Approved, Investigational
Ropinirole	The risk or severity of adverse effects can be increased when Lisinopril is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Ropivacaine.	Approved
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Lisinopril.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Salicylamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Salicylamide.	Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Lisinopril.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril.	Experimental
Saquinavir	The serum concentration of Saquinavir can be increased when it is combined with Lisinopril.	Approved, Investigational
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Lisinopril.	Investigational
Saxagliptin	The risk or severity of adverse effects can be increased when Saxagliptin is combined with Lisinopril.	Approved
Secobarbital	Secobarbital may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Lisinopril.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Lisinopril.	Approved
Seratrodast	The risk or severity of adverse effects can be increased when Lisinopril is combined with Seratrodast.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Lisinopril.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Lisinopril.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Lisinopril.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Lisinopril.	Approved
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Lisinopril.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Lisinopril.	Approved, Investigational
Sitaxentan	Lisinopril may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium aurothiomalate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sodium aurothiomalate.	Approved
Sodium Nitrite	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sodium Nitrite.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Lisinopril.	Approved
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Lisinopril.	Approved, Investigational
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Lisinopril.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Lisinopril.	Experimental
Spirapril	Lisinopril may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril.	Approved
SRT501	The risk or severity of adverse effects can be increased when Lisinopril is combined with SRT501.	Investigational
St. John's Wort	The metabolism of Lisinopril can be increased when combined with St. John's Wort.	Nutraceutical
Streptokinase	The risk or severity of adverse effects can be increased when Lisinopril is combined with Streptokinase.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sufentanil.	Approved, Investigational
Sulfasalazine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sulfasalazine.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sulindac.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Suprofen.	Approved, Withdrawn
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Lisinopril.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Lisinopril.	Approved, Investigational
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Lisinopril.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Lisinopril.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Lisinopril.	Approved
Tamsulosin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tamsulosin.	Approved, Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Lisinopril.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Lisinopril.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lisinopril.	Approved
Telaprevir	The serum concentration of Telaprevir can be increased when it is combined with Lisinopril.	Withdrawn
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril.	Approved, Investigational
Temocapril	Lisinopril may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.	Approved
Tenoxicam	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tenoxicam.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tepoxalin.	Vet Approved
Terazosin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Teriflunomide.	Approved
Terlipressin	Lisinopril may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Lisinopril.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Thioridazine.	Withdrawn
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Lisinopril.	Approved
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tiaprofenic acid.	Approved
Tibolone	Lisinopril may increase the hypotensive activities of Tibolone.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Lisinopril.	Approved
Ticrynafen	Lisinopril may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Lisinopril.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tinoridine.	Investigational
Tinzaparin	Tinzaparin may increase the hyperkalemic activities of Lisinopril.	Approved
Tipranavir	The serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tizanidine	Tizanidine may increase the hypotensive activities of Lisinopril.	Approved
Tolazoline	Lisinopril may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tolfenamic Acid.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tolmetin.	Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Lisinopril.	Approved
Tolvaptan	Tolvaptan may increase the hyperkalemic activities of Lisinopril.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Lisinopril.	Approved, Investigational
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Lisinopril.	Approved
Toremifene	The serum concentration of Toremifene can be increased when it is combined with Lisinopril.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Lisinopril.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tranilast.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lisinopril.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Lisinopril.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Lisinopril.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Lisinopril.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Lisinopril.	Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Lisinopril.	Approved
Trichlormethiazide	Lisinopril may increase the hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Lisinopril may increase the hypotensive activities of Trimazosin.	Experimental
Trimethaphan	Lisinopril may increase the hypotensive activities of Trimethaphan.	Approved
Trimethoprim	Trimethoprim may increase the hyperkalemic activities of Lisinopril.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Lisinopril.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Lisinopril.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Lisinopril.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Lisinopril.	Approved
Unoprostone	Lisinopril may increase the hypotensive activities of Unoprostone.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Lisinopril is combined with Valdecoxib.	Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Lisinopril.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Lisinopril.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Lisinopril.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Lisinopril.	Approved
Venlafaxine	The serum concentration of Venlafaxine can be increased when it is combined with Lisinopril.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Lisinopril.	Approved
Vildagliptin	The risk or severity of adverse effects can be increased when Vildagliptin is combined with Lisinopril.	Approved, Investigational
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Lisinopril.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Lisinopril.	Approved, Investigational
Vinpocetine	Lisinopril may increase the hypotensive activities of Vinpocetine.	Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Lisinopril.	Approved
Xylometazoline	Lisinopril may increase the hypotensive activities of Xylometazoline.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Lisinopril.	Approved, Vet Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Lisinopril is combined with Zaltoprofen.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Lisinopril.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Lisinopril is combined with Zileuton.	Approved, Investigational, Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Lisinopril is combined with Zomepirac.	Withdrawn

Food Interactions

Herbs that may attenuate the antihypertensive effect of lisinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
High salt intake may attenuate the antihypertensive effect of lisinopril.
Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
Take without regard to meals.

References

Synthesis Reference

Vincenzo Cannata, Valeriano Merli, Stefano Saguatti, "Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril." U.S. Patent US6166217, issued September, 1972.

US6166217

General References

Abdelmalek MF, Douglas DD: Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Dig Dis Sci. 1997 Apr;42(4):847-50. [PubMed:9125659 ]
Hasslacher C: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J Diabetes Complications. 1996 May-Jun;10(3):136-8. [PubMed:8807458 ]
Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P: Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009 Sep;32(9):1684-8. doi: 10.2337/dc09-0429. Epub 2009 Jun 5. [PubMed:19502542 ]
Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB01938
KEGG Drug	D00362
PubChem Compound	5362119
PubChem Substance	46504893
ChemSpider	4514933
BindingDB	50367879
ChEBI	43755
ChEMBL	CHEMBL1237
Therapeutic Targets Database	DAP000587
PharmGKB	PA450242
HET	LPR
Drug Product Database	1253
RxList	http://www.rxlist.com/cgi/generic/lisinop.htm
Drugs.com	http://www.drugs.com/lisinopril.html
PDRhealth	http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=zes1498.html&contentName=Zestril&contentId=861
Wikipedia	Lisinopril

ATC Codes

C09AA03 — Lisinopril

C09BB03 — Lisinopril and amlodipine

C10BX07 — Rosuvastatin, amlodipine and lisinopril

C09BA03 — Lisinopril and diuretics

AHFS Codes

24:32.04

PDB Entries

1UZF

FDA label

Download (267 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Not Available	To Determine Bioequivalence Under Fed Conditions	1
1	Completed	Not Available	Type 2 Diabetes Mellitus	1
1	Completed	Basic Science	Gastroparesis	1
1	Completed	Other	Healthy Volunteers	1
1	Completed	Prevention	Hypertensive	1
1	Completed	Treatment	Diabetes / Healthy Volunteers	2
1	Completed	Treatment	Fasting	2
1	Completed	Treatment	Fed	2
1	Completed	Treatment	Hypertensive	5
1	Completed	Treatment	Strokes	1
1	Completed	Treatment	Type 2 Diabetes Mellitus	1
1	Recruiting	Treatment	Hypertension, Resistant to Conventional Therapy	1
1, 2	Completed	Treatment	Pre-Hypertension	1
1, 2	Recruiting	Not Available	Coronary Microvascular Disease	1
2	Active Not Recruiting	Supportive Care	Cancer, Breast / Cardiac Toxicity	1
2	Completed	Treatment	Aging / Cognitive Impairments / Hypertensive	1
2	Completed	Treatment	Glomerulosclerosis, Focal Segmental	1
2	Completed	Treatment	Hypertension,Essential	1
2	Completed	Treatment	Oligozoospermia	1
2	Not Yet Recruiting	Treatment	Albuminuria / Genetic Predisposition / HIV/AIDS / Kidney Diseases	1
2	Recruiting	Treatment	Acute Coronary Syndromes (ACS) / Arterial Hypertension	1
2	Recruiting	Treatment	Extracapillary Glomerulonephritis	1
2	Terminated	Treatment	Hypertensive / Unspecified Adult Solid Tumor, Protocol Specific	1
2, 3	Enrolling by Invitation	Treatment	Becker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD) / Limb Girdle Muscular Dystrophy	1
3	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus	1
3	Completed	Prevention	Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / Hypercholesterolaemia / Hypertensive / Myocardial Infarction (MI) / Myocardial Ischemia	1
3	Completed	Treatment	Hypertensive	3
3	Completed	Treatment	Hypertensive / Obesity, Abdominal	1
3	Completed	Treatment	Kidney, Polycystic	2
3	Completed	Treatment	Left Ventricular Hypertrophy	1
3	Recruiting	Prevention	Hypertensive / Mild Cognitive Impairment (MCI)	1
3	Terminated	Treatment	Heart Failure, Congestive and Microalbuminuria / Hypertensive / Microalbuminuria	1
3	Terminated	Treatment	Hemodialysis-dependent patients / Hypertensive / Left Ventricular Hypertrophy	1
3	Terminated	Treatment	Kidney Diseases / Renal Dysfunction / Type 2 Diabetes Mellitus	1
3	Unknown Status	Treatment	Cardiovascular Disease (CVD)	1
3	Withdrawn	Prevention	Hyperoxaluria	1
4	Completed	Prevention	Perioperative Hypertension	1
4	Completed	Treatment	Diabetic Nephropathies	1
4	Completed	Treatment	Diabetic Nephropathies / Hypertensive	1
4	Completed	Treatment	HIV Disease	1
4	Completed	Treatment	Heart Failure, Unspecified / Ventricular Dysfunction, Left	1
4	Completed	Treatment	Hypertensive	4
4	Completed	Treatment	Stage 2 Diastolic Hypertension	1
4	Not Yet Recruiting	Treatment	Hypertensive	1
4	Recruiting	Treatment	Cardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes	1
4	Recruiting	Treatment	Hypertensive	1
4	Recruiting	Treatment	Proteinuria / Renal Insufficiency,Chronic	1
4	Terminated	Prevention	Cardiovascular Disease (CVD) / Synovitis of osteoarthritis	1
4	Terminated	Prevention	Neurological Dysphagia / Pneumonia	1
4	Unknown Status	Treatment	Hypertension,Essential / Secondary Hypertension	1
4	Unknown Status	Treatment	Hypertensive / Type 2 Diabetes Mellitus	1
Not Available	Active Not Recruiting	Supportive Care	Dyspnea / Lung Cancer Small Cell Lung Cancer (SCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)	1
Not Available	Active Not Recruiting	Treatment	Hypertensive	1
Not Available	Completed	Not Available	Diabetes Complications / Diabetes, Diabetes Mellitus Type 1 / Eye Diseases / Retinopathy, Diabetic	1
Not Available	Completed	Other	Hyperparathyroidism	1
Not Available	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Hypertensive	1
Not Available	Completed	Prevention	BMI >30 kg/m2 / Type 2 Diabetes Mellitus	1
Not Available	Completed	Prevention	Cardiovascular Disease Risk / Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Prevention	Diabetes, Diabetes Mellitus Type 1 / Diabetic Nephropathies	1
Not Available	Completed	Prevention	Diabetic Nephropathies	1
Not Available	Completed	Treatment	BMI >30 kg/m2 / Pre-Diabetic	1
Not Available	Completed	Treatment	Cardiovascular Disease (CVD) / Cerebrovascular Diseases / Peripheral Arterial Disease (PAD)	1
Not Available	Completed	Treatment	Cardiovascular Disease (CVD) / Chronic Kidney Disease (CKD)	1
Not Available	Completed	Treatment	Duchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy	1
Not Available	Completed	Treatment	Hypertension Treatment / Hypertension, Grade 1 / Hypertensive / N of 1 Study Design	1
Not Available	Completed	Treatment	Hypertension,Essential	1
Not Available	Completed	Treatment	Hypertensive / Plasma Renin Activity	1
Not Available	Recruiting	Diagnostic	Arterial Hypertension	1
Not Available	Terminated	Prevention	Thoracic Pain	1
Not Available	Terminated	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Withdrawn	Treatment	Diastolic Heart Failure	1
Not Available	Withdrawn	Treatment	Hypertensive	1

Pharmacoeconomics

Manufacturers

Actavis elizabeth llc
Apotex inc etobicoke site
Aurobindo pharma ltd
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Lek pharmaceuticals d d
Lupin ltd
Mylan pharmaceuticals inc
Ranbaxy pharmaceuticals inc
Sandoz inc
Teva pharmaceuticals usa inc
Vintage pharmaceuticals llc
Watson laboratories inc
West ward pharmaceutical corp
Wockhardt ltd
Merck research laboratories div merck co inc
Astrazeneca uk ltd

Packagers

Advanced Pharmaceutical Services Inc.
Aidarex Pharmacuticals LLC
Amerisource Health Services Corp.
Apotex Inc.
Apotheca Inc.
A-S Medication Solutions LLC
AstraZeneca Inc.
Aurobindo Pharma Ltd.
Blu Pharmaceuticals LLC
Bryant Ranch Prepack
Cardinal Health
Comprehensive Consultant Services Inc.
Coupler Enterprises Inc.
Dept Health Central Pharmacy
DHHS Program Support Center Supply Service Center
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Eon Labs
Golden State Medical Supply Inc.
Greenstone LLC
Group Health Cooperative
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Innoviant Pharmacy Inc.
International Laboratories Inc.
IPR Pharmaceuticals Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Lek Pharmaceuticals Inc.
Liberty Pharmaceuticals
Lupin Pharmaceuticals Inc.
Major Pharmaceuticals
Mckesson Corp.
Medvantx Inc.
Merck & Co.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Neighborcare Repackaging Inc.
Novartis AG
Nucare Pharmaceuticals Inc.
Ohm Laboratories Inc.
Palmetto Pharmaceuticals Inc.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Utilization Management Program VA Inc.
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Prescript Pharmaceuticals
Professional Co.
Promex Medical Inc.
Qualitest
Ranbaxy Laboratories
Rebel Distributors Corp.
Remedy Repack
Resource Optimization and Innovation LLC
Sandhills Packaging Inc.
Sandoz
Southwood Pharmaceuticals
Stat Rx Usa
Stat Scripts LLC
Talbert Medical Management Corp.
Teva Pharmaceutical Industries Ltd.
Torpharm Inc.
Tya Pharmaceuticals
UDL Laboratories
Va Cmop Dallas
Vangard Labs Inc.
Watson Pharmaceuticals
West-Ward Pharmaceuticals
Wockhardt Ltd.

Dosage forms

Form	Route	Strength
Tablet	Oral	40 mg
Tablet	Oral	5 mg
Tablet	Oral	10 mg/301
Tablet	Oral	10 1/1
Tablet	Oral	10 mg/1
Tablet	Oral	2.5 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	30 mg/1
Tablet	Oral	40 mg/1
Tablet	Oral	5 mg/1
Tablet, film coated	Oral	10 mg/1
Tablet, film coated	Oral	2.5 mg/1
Tablet, film coated	Oral	20 mg/1
Tablet, film coated	Oral	30 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet	Oral
Kit
Tablet	Oral	10 mg
Tablet	Oral	2.5 mg
Tablet	Oral	20 mg
Solution	Oral	1 mg/mL

Prices

Unit description	Cost	Unit
Prinivil 90 20 mg tablet Bottle	111.71USD	bottle
Prinzide 30 20-12.5 mg tablet Bottle	45.99USD	bottle
Prinivil 30 2.5 mg tablet Bottle	22.48USD	bottle
Lisinopril 100% powder	21.6USD	g
Zestril 40 mg tablet	2.53USD	tablet
Zestril 30 mg tablet	2.41USD	tablet
Prinivil 40 mg tablet	2.23USD	tablet
Zestoretic 20-25 mg tablet	2.01USD	tablet
Zestoretic 20-12.5 mg tablet	2.0USD	tablet
Prinzide 20-25 mg tablet	1.98USD	tablet
Zestoretic 10-12.5 mg tablet	1.89USD	tablet
Zestoretic 10-12.5 tablet	1.75USD	tablet
Lisinopril 30 mg tablet	1.53USD	tablet
Lisinopril 40 mg tablet	1.44USD	tablet
Prinzide 20-12.5 mg tablet	1.38USD	tablet
Prinzide 10-12.5 mg tablet	1.37USD	tablet
Zestril 20 mg tablet	1.37USD	tablet
Zestril 10 mg tablet	1.33USD	tablet
Zestoretic 20-25 tablet	1.28USD	tablet
Zestril 5 mg tablet	1.28USD	tablet
Zestoretic 20-12.5 tablet	1.26USD	tablet
Lisinopril 20 mg tablet	1.09USD	tablet
Prinivil 20 mg tablet	1.05USD	tablet
Zestril 2.5 mg tablet	1.04USD	tablet
Lisinopril 10 mg tablet	1.01USD	tablet
Prinivil 10 mg tablet	1.01USD	tablet
Lisinopril 5 mg tablet	0.99USD	tablet
Prinivil 5 mg tablet	0.96USD	tablet
Apo-Lisinopril 20 mg Tablet	0.71USD	tablet
Co Lisinopril 20 mg Tablet	0.71USD	tablet
Mylan-Lisinopril 20 mg Tablet	0.71USD	tablet
Novo-Lisinopril (Type P) 20 mg Tablet	0.71USD	tablet
Novo-Lisinopril (Type Z) 20 mg Tablet	0.71USD	tablet
Pms-Lisinopril 20 mg Tablet	0.71USD	tablet
Ran-Lisinopril 20 mg Tablet	0.71USD	tablet
Ratio-Lisinopril P 20 mg Tablet	0.71USD	tablet
Ratio-Lisinopril Z 20 mg Tablet	0.71USD	tablet
Sandoz Lisinopril 20 mg Tablet	0.71USD	tablet
Lisinopril 2.5 mg tablet	0.65USD	tablet
Apo-Lisinopril 10 mg Tablet	0.59USD	tablet
Co Lisinopril 10 mg Tablet	0.59USD	tablet
Mylan-Lisinopril 10 mg Tablet	0.59USD	tablet
Novo-Lisinopril (Type P) 10 mg Tablet	0.59USD	tablet
Novo-Lisinopril (Type Z) 10 mg Tablet	0.59USD	tablet
Pms-Lisinopril 10 mg Tablet	0.59USD	tablet
Ran-Lisinopril 10 mg Tablet	0.59USD	tablet
Ratio-Lisinopril P 10 mg Tablet	0.59USD	tablet
Ratio-Lisinopril Z 10 mg Tablet	0.59USD	tablet
Sandoz Lisinopril 10 mg Tablet	0.59USD	tablet
Apo-Lisinopril 5 mg Tablet	0.49USD	tablet
Co Lisinopril 5 mg Tablet	0.49USD	tablet
Mylan-Lisinopril 5 mg Tablet	0.49USD	tablet
Novo-Lisinopril (Type P) 5 mg Tablet	0.49USD	tablet
Novo-Lisinopril (Type Z) 5 mg Tablet	0.49USD	tablet
Pms-Lisinopril 5 mg Tablet	0.49USD	tablet
Ran-Lisinopril 5 mg Tablet	0.49USD	tablet
Ratio-Lisinopril P 5 mg Tablet	0.49USD	tablet
Ratio-Lisinopril Z 5 mg Tablet	0.49USD	tablet
Sandoz Lisinopril 5 mg Tablet	0.49USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US9463183	No	2015-11-06	2035-11-06	US
US9616096	No	2015-11-06	2035-11-06	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	9.7E+004 mg/L	MERCK INDEX (1996)
logP	-1.01	MERCK INDEX (1996); pH 7
pKa	2.5 (at 25 °C)	MERCK INDEX (1996)

Predicted Properties

Property	Value	Source
Water Solubility	0.216 mg/mL	ALOGPS
logP	-1.2	ALOGPS
logP	-3.1	ChemAxon
logS	-3.3	ALOGPS
pKa (Strongest Acidic)	3.17	ChemAxon
pKa (Strongest Basic)	10.21	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	7	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	132.96 Å²	ChemAxon
Rotatable Bond Count	12	ChemAxon
Refractivity	107.37 m³·mol^-1	ChemAxon
Polarizability	43.5 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.6426
Blood Brain Barrier	-	0.8815
Caco-2 permeable	-	0.7605
P-glycoprotein substrate	Substrate	0.6515
P-glycoprotein inhibitor I	Non-inhibitor	0.9512
P-glycoprotein inhibitor II	Non-inhibitor	0.969
Renal organic cation transporter	Non-inhibitor	0.8574
CYP450 2C9 substrate	Non-substrate	0.8793
CYP450 2D6 substrate	Non-substrate	0.7622
CYP450 3A4 substrate	Non-substrate	0.725
CYP450 1A2 substrate	Non-inhibitor	0.8999
CYP450 2C9 inhibitor	Non-inhibitor	0.9708
CYP450 2D6 inhibitor	Non-inhibitor	0.9653
CYP450 2C19 inhibitor	Non-inhibitor	0.8266
CYP450 3A4 inhibitor	Non-inhibitor	0.907
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9821
Ames test	Non AMES toxic	0.9133
Carcinogenicity	Non-carcinogens	0.9389
Biodegradation	Not ready biodegradable	0.6844
Rat acute toxicity	1.8723 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9641
hERG inhibition (predictor II)	Non-inhibitor	0.8708

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)	splash10-0a4r-0194100000-d9a47a283478b88bb101	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)	splash10-001i-9040000000-8d6d4ae6ba18da11e336	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)	splash10-001i-9000000000-77e20f7eb799eea58ab0	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-qTof , Positive	Not Available
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-qTof , Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
1D NMR	1H NMR Spectrum	Not Available
2D NMR	[1H,13C] 2D NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Dipeptides

Alternative Parents

Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Benzene and substituted derivatives / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides

Substituents

Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

dipeptide (CHEBI:43755 )

Targets

Details

1. Angiotensin-converting enzyme

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Zinc ion binding
Specific Function:: Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:: ACE
Uniprot ID:: P12821
Uniprot Name:: Angiotensin-converting enzyme
Molecular Weight:: 149713.675 Da

References

Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
Tellez-Sanz R, Garcia-Fuentes L, Baron C: Calorimetric analysis of lisinopril binding to angiotensin I-converting enzyme. FEBS Lett. 1998 Feb 13;423(1):75-80. [PubMed:9506845 ]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:31

Structure for DB00722 (Lisinopril)

Targets

References